|
The effect of rosuvastatin on inflammatory and oxidative markers in asthmatic rats with hyperlipidemia
|
Saeideh Saadat   , Mohammad Hossein Boskabady |
|
|
|
Abstract: (235 Views) |
Introduction: Asthma is an inflammatory disorder, and hypercholesterolemia increases the risk of asthma by promoting a similar pro-inflammatory status in the airway. In this study, the effect of rosuvastatin on asthmatic, hyperlipidemic, and hyperlipidemic-asthmatic rat models was investigated.
Methodes and Materials: To induce hyperlipidemia, rats received a normal diet plus 10% ethanol and 10% fructose in drinking water for 9 weeks. Rats were sensitized by intraperitoneal injection and inhalation of ovalbumin for 3 weeks. Inflammatory and oxidative markers and lung pathological changes were evaluated in control, asthmatic, hyperlipidemic, hyperlipidemic-asthmatic, rosuvastatin (40 mg/kg/day intraperitoneally, 3 weeks)-treated asthmatic, rosuvastatin-treated hyperlipidemic and rosuvastatin-treated hyperlipidemic-asthmatic groups.
Results: Diet-induced hyperlipidemia caused a significant increase in serum lipid profiles, an oxidant/antioxidant imbalance in serum, and an elevation in levels of IL-4 and IFN-γ (p<0.05 to p<0.001). The induction of asthma increased tracheal responsiveness to methacholine and ovalbumin, total and differential WBC count, oxidative stress parameters, levels of IL-4, IL-10, and IL-17, decreased IFN-γ level and Th1/Th2 ratio, and caused pathological changes (p<0.05 to p<0.001). Beyond the lipid-lowering effect in treated hyperlipidemic and hyperlipidemic-asthmatic groups, rosuvastatin treatment decreased tracheal responsiveness to methacholine, reduced total and differential WBC count, and lung oxidative stress in serum and BALF, and caused a reduction in BALF levels of IL-4, IL-6, and IL-17 (p<0.05 to p<0.001). Moreover, pathological changes including inflammation, muscle hypertrophy and emphysema were improved in the rosuvastatin treated groups (p<0.05 to p<0.001).
Conclusion: Rosuvastatin improved lung inflammation and oxidative stress not only in hyperlipidemic-asthmatic rat model, but also in the allergic asthma rat model. This study suggests that important pleiotropic mechanisms may be responsible for immunomodulatory, anti-inflammatory, and anti-oxidant effects of rosuvastatin that are independent of its lipid lowering effect. Rosuvastatin probably reduces allergic diseases by reducing the Th17 immune responses and switching from Th2 to Th1 immune response.
|
|
| Keywords: Rosuvastatin, Asthma, Hyperlipidemia, Inflammation, Oxidative stress |
|
|
Full-Text [PDF 326 kb]
(35 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2024/01/31 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
